If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
820.00    16.00 (1.99%)
Bid:
824.00
Ask:
832.00
Spread: 8.00 (0.971%)
Market Cap: £377.99m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Acquisition and Trading Update

5 Jun 2013 07:00

RNS Number : 2950G
Porvair PLC
05 June 2013
 

For immediate release 5 June 2013

 

Porvair plc ("Porvair" or "The Group")

 

Acquisition and Trading Update

 

Porvair, the specialist filtration and environmental technologies group, today announces the acquisition of the business of Eisenmann Metallurgical LLC and issues a trading update ahead of the publication of its interim results for the six months ended 31 May 2013 on 24 June 2013.

 

The Group's Microfiltration division has acquired the goodwill, business and trading assets of Eisenmann Metallurgical LLC, trading as Chand Eisenmann Metallurgical ("CEM"), for a total consideration of US$5.5 million in cash and loans. CEM designs and manufactures specialist filters from a facility in Caribou, Maine. There is a good commercial fit between CEM and Porvair's existing product portfolio. With clear cross-selling opportunities, the combined business is well positioned to accelerate its rate of growth in the US. The transaction is expected to be immediately earnings accretive.

 

The Group has started 2013 well and expects to report interim profits well ahead of 2012. Several major contracts were announced earlier in the year and will support Group performance over the next few years. All are on schedule and have begun to contribute to results. Group revenue is expected to be around 7% ahead of the first six months of 2012 at constant currency rates. Order books are strong in Microfiltration and market share gains continue to be made in Metals Filtration.

 

An analyst briefing will be held at 9.30 a.m. at Buchanan, 107 Cheapside, London, EC2V 6DN on the day of the interim results, Monday 24 June 2013.

 

Commenting on the acquisition and trading, Ben Stocks, Chief Executive, said:

 

"CEM is a highly complementary bolt-on acquisition which broadens our product range, geographic spread and materials expertise. Its staff, based in Caribou, Maine, are skilled and highly experienced and are warmly welcomed to the Group. There are many cross-selling opportunities apparent in this transaction and we plan to invest in the Caribou facility over the next 12 months to accommodate the expected growth.

 

Trading in the first half of 2013 has been satisfactory, and the prospects for the second half; supported by our order books, recent large engineering contracts, and the CEM acquisition; are good."

 

For more information, contact:

 

Porvair plc

Ben Stocks, Chief Executive

01553 765 500

Chris Tyler, Group Finance Director

01553 765 500

Buchanan

0207 466 5000

Charles Ryland / Helen Greenwood / Clare Akhurst

www.buchanan.uk.com

 

 

Notes to Editors

Porvair is a group of specialist filtration and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. Its principal markets are aviation, energy and industrial process, environmental laboratories and non-ferrous metals.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSANROBANRAR
Date   Source Headline
14th Dec 202112:25 pmRNSDirector Declaration
9th Dec 20217:00 amRNSPre-close trading update and Notice of Results
23rd Nov 202112:30 pmRNSHolding(s) in Company
5th Nov 20214:40 pmRNSSecond Price Monitoring Extn
5th Nov 20214:35 pmRNSPrice Monitoring Extension
8th Oct 20214:40 pmRNSSecond Price Monitoring Extn
8th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Sep 20214:41 pmRNSSecond Price Monitoring Extn
27th Sep 20214:35 pmRNSPrice Monitoring Extension
16th Sep 20213:31 pmRNSDirector/PDMR Shareholding
14th Sep 20217:00 amRNSNine Month Trading Update
11th Aug 20214:41 pmRNSSecond Price Monitoring Extn
11th Aug 20214:35 pmRNSPrice Monitoring Extension
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20217:00 amRNSBlock listing Interim Review
5th Jul 20217:00 amRNSHalf Year Results 2021
30th Jun 20217:00 amRNSTotal Voting Rights
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:36 pmRNSPrice Monitoring Extension
23rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
10th May 20214:40 pmRNSSecond Price Monitoring Extn
10th May 20214:36 pmRNSPrice Monitoring Extension
21st Apr 20212:40 pmRNSGrant of LTSP awards
20th Apr 202112:30 pmRNSAGM resolutions and Board changes
20th Apr 20217:00 amRNSAGM Trading Update
1st Apr 20214:28 pmRNSTotal Voting Rights
17th Mar 20214:57 pmRNSHolding(s) in Company
16th Mar 20212:01 pmRNSHolding(s) in Company
2nd Mar 20214:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20213:27 pmRNSTotal Voting Rights
26th Feb 20217:00 amRNSAcquisition of Kbiosystems Limited
22nd Feb 20213:00 pmRNSHolding(s) in Company
19th Feb 20214:35 pmRNSPrice Monitoring Extension
10th Feb 20214:36 pmRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSBlock listing Interim Review
8th Feb 20217:00 amRNSTotal Voting Rights
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
3rd Feb 20219:42 amRNSHolding(s) in Company
2nd Feb 20217:00 amRNSGrant of LTSP awards
1st Feb 20217:00 amRNSFinal Results
6th Jan 20214:41 pmRNSSecond Price Monitoring Extn
6th Jan 20214:35 pmRNSPrice Monitoring Extension
30th Dec 20203:30 pmRNSHolding(s) in Company
30th Dec 20203:30 pmRNSHolding(s) in Company
9th Dec 20203:47 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSPre-close trading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.